别嘌醇与常规治疗在英国缺血性心脏病患者中的比较(ALL-HEART):多中心、前瞻性、随机、开放标签、盲法终点试验
ALL-HEART 研究在英格兰和苏格兰 18 个区域中心、424 家初级保健诊所纳入 60 岁及以上、无痛风史的缺血性心脏病患者,随机接受口服别嘌醇(上调至每日 600 mg,基线中度肾功能不全者每日 300 mg)或常规治疗。改良意向治疗人群 5721 例(别嘌醇组 2853 例、常规治疗组 2868 例),平均随访 4.8 年,主要复合心血管终点发生率两组无差异(HR 1.04,95%CI 0.89-1.21,p=0.65)。
要点
- 60 岁及以上缺血性心脏病且无痛风史患者中,别嘌醇组与常规治疗组主要心血管复合终点无差异。
- 别嘌醇组 314 例(11.0%)发生主要终点,常规治疗组 325 例(11.3%),HR 1.04(95%CI 0.89-1.21),p=0.65。
- 全因死亡别嘌醇组 288 例(10.1%)、常规治疗组 303 例(10.6%),HR 1.02(95%CI 0.87-1.20),p=0.77。
核心结论
- 在 60 岁及以上、有缺血性心脏病但无痛风史的患者中,别嘌醇治疗组与常规治疗组在非致死性心肌梗死、非致死性卒中或心血管死亡组成的主要终点上无差异。
研究设计与样本
- 多中心、前瞻性、随机、开放标签、盲法终点试验,在英格兰和苏格兰 18 个区域中心开展,患者来自 424 家初级保健诊所。
- 纳入 60 岁及以上、有缺血性心脏病但无痛风史的患者,1:1 随机分配至口服别嘌醇组(上调至每日 600 mg,基线中度肾功能不全者每日 300 mg)或继续常规治疗组。
- 共 5937 例入组并随机分配,排除随机后 216 例,改良意向治疗人群 5721 例(别嘌醇组 2853 例、常规治疗组 2868 例),平均年龄 72.0 岁(SD 6.8),男性 4321 例(75.5%),白人 5676 例(99.2%)。
- 主要终点为非致死性心肌梗死、非致死性卒中或心血管死亡的复合终点,采用 Cox 比例风险模型评估优效性;安全性分析人群包括改良意向治疗常规治疗组全部患者及别嘌醇组至少服用一剂随机药物的患者。
- 研究于 2014 年 2 月 7 日至 2017 年 10 月 2 日入组,平均随访 4.8 年(1.5)。
主要发现
- 主要终点:别嘌醇组 314 例(11.0%,每 100 患者年 2.47 次事件)vs 常规治疗组 325 例(11.3%,每 100 患者年 2.37 次事件),HR 1.04(95%CI 0.89-1.21),p=0.65。
- 全因死亡:别嘌醇组 288 例(10.1%)vs 常规治疗组 303 例(10.6%),HR 1.02(95%CI 0.87-1.20),p=0.77。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous studies have shown that allopurinol has positive effects on several cardiovascular parameters. The ALL-HEART study aimed to determine whether allopurinol therapy improves major cardiovascular outcomes in patients with ischaemic heart disease. METHODS: ALL-HEART was a multicentre, prospective, randomised, open-label, blinded-endpoint trial done in 18 regional centres in England and Scotland, with patients recruited from 424 primary care practices. Eligible patients were aged 60 years or older, with ischaemic heart disease but no history of gout. Participants were randomly assigned (1:1), using a central web-based randomisation system accessed via a web-based application or an interactive voice response system, to receive oral allopurinol up-titrated to a dose of 600 mg daily (300 mg daily in participants with moderate renal impairment at baseline) or to continue usual care. The primary outcome was the composite cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. The hazard ratio (allopurinol vs usual care) in a Cox proportional hazards model was assessed for superiority in a modified intention-to-treat analysis (excluding randomly assigned patients later found to have met one of the exclusion criteria). The safety analysis population included all patients in the modified intention-to-treat usual care group and those who took at least one dose of randomised medication in the allopurinol group. This study is registered with the EU Clinical Trials Register, EudraCT 2013-003559-39, and ISRCTN, ISRCTN32017426. FINDINGS: Between Feb 7, 2014, and Oct 2, 2017, 5937 participants were enrolled and then randomly assigned to receive allopurinol or usual care. After exclusion of 216 patients after randomisation, 5721 participants (mean age 72·0 years [SD 6·8], 4321 [75·5%] males, and 5676 [99·2%] white) were included in the modified intention-to-treat population, with 2853 in the allopurinol group and 2868 in the usual care group. Mean follow-up time in the study was 4·8 years (1·5). There was no evidence of a difference between the randomised treatment groups in the rates of the primary endpoint. 314 (11·0%) participants in the allopurinol group (2·47 events per 100 patient-years) and 325 (11·3%) in the usual care group (2·37 events per 100 patient-years) had a primary endpoint (hazard ratio [HR] 1·04 [95% CI 0·89-1·21], p=0·65). 288 (10·1%) participants in the allopurinol group and 303 (10·6%) participants in the usual care group died from any cause (HR 1·02 [95% CI 0·87-1·20], p=0·77). INTERPRETATION: In this large, randomised clinical trial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there was no difference in the primary outcome of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death between participants randomised to allopurinol therapy and those randomised to usual care. FUNDING: UK National Institute for Health and Care Research.
引用
- Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022. PMID: 36216006. doi:10.1016/S0140-6736(22)01657-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。